Publications by authors named "Siru Zhao"
This study developed a stable nanoparticle (CUR-SPIH/SSPS) using soybean protein isolate hydrolysate (SPIH) and soybean polysaccharides (SPSS) to protect curcumin (CUR) from degradation during storage and exposure to light and heat conditions, achieving controlled release. The SPIH to SPSS mass ratio of 5:1 gave the CUR-SPIH/SPSS nanoparticles with the highest CUR encapsulation efficiency (95.60 ± 3.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on creating a prognostic model to predict HBsAg loss in patients with chronic hepatitis B (CHB) undergoing antiviral treatment, which currently rarely occurs with existing therapies.
- Data from 6,792 patients treated with nucleos(t)ide analogues were analyzed, leading to the development of the GOLDEN model that integrates longitudinal HBsAg measurements.
- The GOLDEN model demonstrated high accuracy in predicting HBsAg clearance, effectively identifying patients likely to achieve this outcome, which could improve patient stratification in future treatments.
Background: Whether different anti-hepatitis B virus (HBV) drugs have different effects on COVID-19 is controversial. We aimed to evaluate the incidence of COVID-19 in chronic hepatitis B (CHB) patients receiving anti-HBV treatment, and to compare the impact of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) on the severity of COVID-19.
Methods: CHB outpatients were enrolled from December 2022 to February 2023.
Background & Aims: Current hepatocellular carcinoma (HCC) risk scores do not reflect changes in HCC risk resulting from liver disease progression/regression over time. We aimed to develop and validate two novel prediction models using multivariate longitudinal data, with or without cell-free DNA (cfDNA) signatures.
Methods: A total of 13,728 patients from two nationwide multicenter prospective observational cohorts, the majority of whom had chronic hepatitis B, were enrolled.
Background: The immune response and safety of inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines among patients with chronic hepatitis B (CHB), especially those with cirrhosis, are not clear. Therefore, this study was conducted to evaluate the efficacy and safety of inactivated SARS-CoV-2 vaccines among CHB patients with and without cirrhosis.
Patients And Methods: A total of 643 CHB patients who received two doses of inactivated SARS-CoV-2 vaccines (BBIBP-CorV and CoronaVac) were enrolled.
The impact of long-term nucleos(t)ide analogs treatment on host metabolism is a concern. Hence, we conducted this study to compare the effect of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) on metabolic parameters among chronic hepatitis B (CHB) patients. In this real-life retrospective study, 2030 CHB outpatients treated with ETV or TDF at Nanfang Hospital, China, were included.
View Article and Find Full Text PDFBackground: Sexual dysfunction (SD) is an increasingly serious global problem that has adverse effects on the physical and mental health of patients.
Aim: This study aimed to investigate the prevalence of SD and its related factors in patients with chronic hepatitis B (CHB).
Methods: A total of 673 outpatients with CHB from October 2019 to December 2020 were included in the analysis.
Background: Whether serum hepatitis B virus (HBV) RNA associates with hepatocellular carcinoma (HCC) development in chronic hepatitis B (CHB) patients has not been fully elucidated.
Methods: We enrolled 2974 patients receiving nucleos(t)ide analogues (NAs) from a prospective, observational CHB cohort to investigate the effect of serum HBV RNA, measured at study entry (baseline), on HCC development, using Cox regression analyses.
Results: During median follow-up of 4.